See the DrugPatentWatch profile for yervoy

While Yervoy (ipilimumab) is a medication primarily used for the treatment of melanoma, there may be exceptions to discounts offered for the drug. Bristol-Myers Squibb, the pharmaceutical company that manufactures Yervoy, has engaged in collaborations and partnerships, such as the one with Nektar Therapeutics for the development and commercialization of Nektar's CD122 biased agonist NKTR-214 [2]. These collaborations could potentially impact any discount programs or pricing strategies for Yervoy.

Furthermore, the European Medicines Agency (EMA) provides detailed product information for Yervoy, which includes information on pricing, reimbursement, and discounts within the European Union [3]. This document may shed light on any exceptions or specific conditions related to discounts for Yervoy in the EU.

It is essential for patients and healthcare providers to stay informed about any changes in pricing, discounts, or access programs for Yervoy by monitoring official announcements from Bristol-Myers Squibb, regulatory agencies, and healthcare authorities.

Sources:
[2] https://news.bms.com/news/partnering/2018/Bristol-Myers-Squibb-and-Nektar-Therapeutics-Announce-Global-Development--Commercialization-Collaboration-for-Nektars-CD122-biased-Agonist-NKTR-214/default.aspx
[3] https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf